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Title  
Left Ventricular Extracellular Volume Fraction and Atrio-Ventricular Interaction in 
Hypertension 
 
Abstract 
Objectives 
Left atrial enlargement (LAE) predicts cardiovascular morbidity and mortality. Impaired 
LA function also confers poor prognosis. This study aimed to determine whether left 
ventricular (LV) interstitial fibrosis is associated with LAE and LA impairment in 
systemic hypertension. 
 
Methods 
Following informed written consent, a prospective observational study of 86 
hypertensive patients (49±15 years, 53% male, office SBP 168±30mmHg, office DBP 
97± 4 mmHg) and 20 normotensive controls (48±13 years, 55% male, office SBP 
130±13 mmHg, office DBP 80±11 mmHg) at 1.5T cardiovascular magnetic resonance 
was conducted. Extracellular volume fraction (ECV) was calculated by T1 mapping. LA 
volume (LAV) was measured with biplane area-length method. LA reservoir, conduit 
and pump function were calculated with the phasic volumetric method.  
 
Results 
Indexed LAV correlated with indexed LV mass (R=0.376, p<0.0001) and ECV (R=0.359, 
p=0.001). However, ECV was the strongest significant predictor of LAE in multivariate 
regression analysis (odds ratio [95th confidence interval]: 1.24 [1.04–1.48], p=0.017). 
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Indexed myocardial interstitial volume was associated with significant reductions in LA 
reservoir (R=-0.437, p<0.0001) and conduit (R=-0.316, p=0.003) but not pump  (R=-
0.167, p=0.125) function. Multiple linear regression, correcting for age, gender, BMI, 
BP and diabetes, showed an independent decrease of 3.5% LA total emptying fraction 
for each 10ml/m2 increase in myocardial interstitial volume (standard β coefficient: -
3.54, p=0.002). 
 
Conclusions 
LV extracellular expansion is associated with LAE and impaired LA reservoir and 
conduit function. Future studies should identify if targeting diffuse LV fibrosis is 
beneficial in reverse remodeling of LA structural and functional pathological 
abnormalities in hypertension. 
 
Key words 
Cardiac Imaging Techniques; Magnetic Resonance Imaging; Hypertension; Fibrosis; 
Strain 
 
Key points 
• Left atrial enlargement (LAE) and impairment are markers of adverse prognosis 
in systemic hypertension but their pathophysiology is poorly understood. 
• Left ventricular extracellular volume fraction was the strongest independent 
multivariate predictor of LAE and was associated with impaired left atrial 
reservoir and conduit function. 
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• LV interstitial expansion may play a central role in the pathophysiology of 
adverse atrio-ventricular interaction in systemic hypertension. 
Abbreviations 
 LA  - Left atrial 
LAE  - Left atrial enlargement 
LVH  - Left ventricular hypertrophy 
LV  - Left ventricular 
CMR  - Cardiovascular magnetic resonance 
SBP  - Systolic blood pressure 
DBP  - Diastolic blood pressure 
SSFP  - Steady state free precession 
LVM  - Left ventricular mass 
LAV  - Left atrial volume 
LAVmin - Minimal left atrial volume 
LAVpre-A - Left atrial volume just prior to left atrial contraction 
LAVmax - Maximal left atrial volume 
EDV  - End-diastolic volume 
ESV  - End-systolic volume 
SV  - Stroke volume 
ROI  - Region of interest 
ECV  - Extracellular volume fraction 
ANOVA - Analysis of variance 
BMI  - Body mass index 
ESC  -  European Society of Cardiology 
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Introduction 
Left atrial (LA) enlargement (LAE) is common in hypertension[1] and postulated to be 
compensatory to left ventricular hypertrophy (LVH) associated diastolic dysfunction. 
However, LAE may develop before LVH in hypertension[2] and LAE is an independent 
predictor of cardiovascular morbidity and mortality[3].  
 
Atrio-ventricular interaction is important; LA function is intimately related to left 
ventricular (LV) compliance. As LV compliance falls, LA pump function contributes 
proportionately more to LV filling[4]. However, as LV compliance falls further, LA pump 
function declines and the LA reverts to mainly functioning as a passive conduit[5]. In 
hypertension, LA pump function has been shown to be an independent predictor of 
adverse cardiac events[6].  
 
However, the pathophysiology of LA dilatation and dysfunction in hypertension 
remains poorly understood. This assessed atrio-ventricular interaction using multi-
parametric cardiovascular magnetic resonance (CMR), to investigate the relationship 
between LV interstitial expansion, a surrogate for diffuse LV fibrosis, and LA 
size/function. The hypothesis was that increasing LV interstitial expansion would be 
associated with LAE and impaired LA function. 
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Methods  
Ethics approval and participants  
A prospective, observational study of hypertensive patients from a tertiary 
hypertension clinic undergoing CMR was performed (February 2013–April 2016). The 
local research ethics committee confirmed the study conformed to governance 
arrangements. Subjects provided informed, written consent. Baseline demographic 
and clinical characteristics were recorded. Average office systolic (SBP) and diastolic 
blood pressures (DBP) were acquired in accordance with International hypertension 
guidelines[7]. Exclusion criteria were: atrial fibrillation, concomitant myocardial 
pathology that may confound LAE (e.g. moderate-severe valvular disease and 
acquired/inherited cardiomyopathy) and estimated glomerular filtration rate 
<30ml/min/1.73m2. Normotensive healthy volunteers acted as controls, but did not 
receive intravenous gadolinium chelate due to ethics approval constraints. 
 
CMR cine protocol 
1.5T CMR was performed (Avanto, Siemens Healthineers). Short-axis steady-state free 
precession (SSFP) cines with whole LV coverage (8mm slice thickness, no slice gap, 
temporal resolution 38.1ms, echo time 1.07ms, representative field of view 300mm, 
image matrix 152x192, in-plane pixel size 1.6x1.6mm) were used to measure LV mass 
(LVM) and volumes, which were indexed to body surface area (Mosteller formula) as 
before[8].  
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LA enlargement and function analysis 
LA volume (LAV) was measured by biplane area-length[9](Figure 1) as follows: 
LAV = 0.85 x A4c x A2c / L 
Where: 
A4c = LA area on 4-chamber cine at end-systole 
A2c = LA area on 2-chamber cine at end-systole 
L = shortest LA length on either 4-chamber or 2-chamber at end-systole 
 
LA function was assessed using the phasic-volumetric method[10](Figure 2) that 
measures LAV at 3 phases of the cardiac cycle reliably[6]:  
 
1) Minimal LAV (LAVmin) at LV end-diastole at mitral valve closure  
 
2) Just prior to LA contraction (LAVpre-A) 
 
3) Maximal LAV (LAVmax) at end-systole just prior to mitral valve opening.  
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LA function was estimated as[10]: 
 
1) LA reservoir function:  
LA total emptying fraction = (LAVmax – LAVmin) / LAVmax x 100% 
 
2) LA conduit function:  
LA passive emptying fraction = (LAVmax – LAVpre-A) / LAVmax x 100% 
 
3) LA pump function:  
LA active emptying = (LAVpre-A – LAVmin) / LAVpre-A x 100% 
 
LA expansion index was defined as previously[11][12][13] as: 
(LAVmax – LAVmin) / LAVmin x 100% 
 
LAE was defined as indexed LAVmax ≥55ml/m2, which is larger than echocardiographic 
cut-off values[14] but more appropriate for CMR as it represents 2 standard deviations 
above the CMR mean of healthy subjects[15][16]. Furthermore, a recent publication of 
804 normal volunteers confirmed indexed LAVmax 55ml/m2 as the upper limit of 
normal for men and women[17]. 
 
LV volume, mass and functional analysis 
A validated and highly reproducible[18] threshold-detection software (CMR42, Circle 
Cardiovascular Imaging Inc.) was used to include papillary muscles and LV trabeculae in 
LVM estimation and then include them in blood-pool volume for end-diastolic (EDV), 
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end-systolic (ESV) and stroke (SV) volume measurements as before[8]. CMR analysis 
was performed blinded to all other data.  
 
CMR T1-mapping protocol and analysis 
Myocardial T1-mapping was performed using a modified look-locker inversion 
recovery sequence with native and post-contrast sequences dependent upon heart 
rate at acquisition (Table 1). Constant scan parameters were: flip angle 35o, GRAPPA 
acceleration factor 2, bandwidth 1085 Hz/Px, number of inversions 2, starting TI 
120ms, TI increment 80ms. Regions of interest (ROI) were drawn within mid-septum 
on short-axis, motion-corrected, native T1-maps and copied onto corresponding 15 
minutes post-contrast maps, adjusting for partial-voluming and/or artifact, as 
previously described[19]. Argus software (Siemens, Germany) was used for T1 analysis, 
as previously described[19]. Extracellular volume fraction (ECV) was calculated using 
an established formula[19]:  
 
ECV = (ΔR1myocardium/ ΔR1blood-pool) x (1 – haematocrit) 
Where:  
ΔR1 = (1/post-contrast T1 – 1/native T1).  
Haematocrit measured from peripheral venous blood sample. 
 
Indexed interstitial volume was calculated by multiplying the ECV by indexed 
myocardial volume (indexed LVM divided by myocardial specific gravity 1.05g/ml). 
Myocardial cell volume fraction was defined, as previously[20], as (1–ECV), and 
multiplied by indexed LV myocardial volume to generate an estimation of indexed 
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myocardial cell volume. Excellent reproducibility was demonstrated in a subset of 50 
subjects (native T1-mapping intra-class correlation coefficient (ICC): 0.968 (95th 
confidence interval: 0.951–0.984) and ECV ICC: 0.988 (95th confidence interval: 0.979–
0.993). 
 
CMR strain imaging 
Strain imaging was performed offline by software (Tissue Tracking, CMR42, Circle 
Cardiovascular Imaging Inc.) that tracks myocardial voxels through the cardiac cycle in 
2D, based on a previously described algorithm[21][22]. Briefly, the endocardial and 
epicardial borders (excluding papillary muscles and trabeculae) and the mitral valve 
annular plane at end-diastole were defined on LV 4-chamber, LV 2-chamber and whole 
LV short-axis SSFP cine images. Circumferential strain and strain rates were calculated 
from mean values of mid LV myocardial segments from the short-axis 2-dimensional 
strain model. Srain analysis was performed blinded to all other data. 
 
Statistical analysis 
Statistical analysis was performed in SPSS (v.21, IBM Corp). A power calculation could 
not be performed for this exploratory observational study because there are no 
previous studies assessing the atrio-ventricular interaction using non-invasive 
measures of LV diffuse interstitial fibrosis and LA phasic volume function using any 
cardiac imaging modality. Normally distributed continuous variables were expressed as 
mean ± standard deviation and compared using analysis of variance (ANOVA) with 
Bonferroni post-hoc correction. Categorical variables were expressed as percentages 
and interrogated with Chi-square tests. Correlations were assessed with Pearson’s 
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coefficient. General linear models were used to correct for differences in baseline 
covariates of age, gender, body mass index (BMI), diabetes, office SBP, office DBP and 
number of anti-hypertensive medications between cohorts. Multiple linear regression 
was preformed to quantify independent impact of indexed interstitial and myocardial 
cell volumes on indexed LAVmax, LAVmin and LA total emptying fraction, accounting 
for covariates. Univariate logistic regression identified predictors of LAE and significant 
univariate variables were tested in a multivariate model to determine independent 
associations. P<0.05. 
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Results 
Participant demographics 
116 hypertensive patients were assessed for eligibility. 30 patients were 
excluded(Figure 3), with final sample size of 86 (49±15 years, 53% male, office SBP 
168±30mmHg, office DBP 97±4mmHg). 20 normotensive control subjects were 
recruited (48±13 years, 55% male, office SBP 130±13mmHg, office DBP 80±11mmHg). 
Hypertensive and normotensive subjects were age- and sex-matched(Table 2). LAE 
was present in 27% (n=23).  
 
LA size and LV mass 
Indexed LVM correlated with indexed LAVmax (R=0.376, P<0.0001)(Figure 4A) and 
with indexed LAVmin (R=0.616, P<0.0001)(Figure 4B). 
 
Hypertensive subjects with LAE had higher: 1) indexed LVM mass (97±33g/m2 vs 
84±22g/m2, P=0.044), 2) indexed EDV (89±17ml/m2 vs 73±16ml/m2, P<0.0001) and 3) 
indexed ESV (34±17ml/m2 vs 24±10ml/m2, P<0.0001) compared to hypertensive 
subjects without LAE(Table 3), which persisted after correcting for covariates(Table 4). 
 
LA size, LV fibrosis and LV strain 
There was a positive correlation between ECV and 1) indexed LAVmax (R=0.359, 
P=0.001)(Figure 4C) and 2) indexed LAVmin (R=0.390,  P<0.0001)(Figure 4D). 
Hypertensives with LAE had higher ECV (30±4% vs 27±3%, P=0.003)(Table 2) and larger 
indexed LV interstitial volume (28±12ml/m2 vs 21±7ml/m2, P=0.043) than 
hypertensives without LAE(Table 3), which persisted after correcting for covariates 
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(Table 4). However, there was no significant difference in indexed LV myocardial cell 
volume between hypertensive subjects with LAE and those without LAE (64±21ml/m2 
vs 57±15ml/m2, P=0.106)(Table 3). 
 
Accounting for the covariates of age, gender, BMI, diabetes, office SBP and office DBP, 
each 10ml/m2 increase in indexed LV interstitial volume, a significant independent 
increase in 1) indexed LAVmax of 4.9ml/m2 (standard β coefficient: 4.88, P<0.0001) 
and 2) indexed LAVmin of 5.6ml/ m2 occurs (standard β coefficient: 5.61, P<0.0001). In 
a separate model, each 10ml/m2 increase in indexed LV myocardial cell volume, was 
also associated with a significant independent increase in 1) indexed LAVmax of 
3.2ml/m2 (standard β coefficient: 3.20, P<0.0001) and 2) indexed LAVmin of 4.7ml/ m2 
(standard β coefficient: 4.74, P<0.0001). 
 
Indexed interstitial volume correlated with peak circumferential strain (R=0.454, 
p<0.0001), peak systolic strain rate (R=0.342, p=0.001) and peak diastolic strain rate 
(R=-0.380, p<0.0001). Indexed myocardial cell volume also correlated with peak 
circumferential strain (R=0.509, p<0.0001), systolic strain rate (R=0.267, p=0.013) and 
diastolic strain rate (R=-0.501, p<0.0001). In turn, indexed LAVmin correlated with 
peak circumferential strain (R=0.275, p=0.01), systolic strain rate (R=0.438, p<0.0001) 
and diastolic strain rate (R=-0.273, p=0.011).  However, LAVmax only correlated with 
systolic strain rate (R=0.405, p<0.0001) and not with peak circumferential strain 
(R=0.067, p=0.537) or diastolic strain rate (R=-0.136, p=0.212). 
 
Predictors of LAE 
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Indexed LVM, ECV and peak circumferential strain rate were significant predictors of 
LAE in univariate logistic regression(Table 5). ECV and peak circumferential strain rate 
remained significant predictors in the multivariate model and ECV was the strongest 
predictor (Table 5). 
 
LA function and LV fibrosis 
Indexed LV interstitial volume inversely correlated with LA total reservoir function (R=-
0.437, P<0.0001)(Figure 5A). Likewise, indexed LV interstitial volume inversely 
correlated with LA passive conduit function (R=-0.316, P=0.003)(Figure 5B). However, 
there was no significant correlation between indexed LV interstitial volume and LA 
pump function (R=-0.167, P=0.125)(Figure 5C). There was a significant decrease in LA 
expansion index with increasing interstitial volume (R=-0.377, P<0.0001)(Figure 5D). 
 
Accounting for the covariates of age, gender, BMI, diabetes, office SBP and office DBP, 
each 10ml/m2 increase in indexed LV interstitial volume, a significant independent 
decrease in LA total reservoir function of 3.5% occurs (standard β coefficient: -3.54, 
P=0.002). In a separate model, each 10ml/m2 increase in indexed LV myocardial cell 
volume, was associated a significant independent decrease in LA total reservoir 
function of 3.2% (standard β coefficient: -3.20, P=0.006).
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Discussion 
We demonstrate the relationship between LV interstitial expansion and LA structure 
and function in hypertension using CMR. Previous studies have investigated using 
with T1 mapping techniques in hypertensive patients[23][24][25][26][27], but all 
have focused exclusively on the LV, with no focus on atrio-ventricular interaction, 
which has been addressed in the current study. Our novel findings are: 1) increasing 
LV interstitial volume is associated with increasing LAVmax and LAVmin. 2) 
increasing LV interstitial volume is also associated with impaired circumferential 
systolic and diastolic strain rate that are in turn correlate with LAVmin, 3) Increasing 
LV ECV was the strongest independent multivariate predictor of LAE, and 4) LV 
interstitial fibrotic burden significantly inversely correlates with LA total reservoir 
function and in LA passive conduit function but not with LA active pump function.  
 
Atrio-ventricular interaction 
Hypertensive LV changes are intimately related to LA dynamics. A recent 
echocardiographic study showed that LV systolic and diastolic dysfunction were 
associated with increased LAV and LA diastolic stiffness, even in asymptomatic 
patients[28]. Our study provides further insight at the LV myocardial 
intra/extracellular level. Although both increases in indexed myocardial cell volume 
and indexed interstitial volume were independently associated with LAE, the 
regression coefficient was larger for indexed interstitial volume. Furthermore, ECV 
was the only independent predictor of LAE in multivariate regression analysis. 
 
Potential for LA reverse remodeling.  
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We demonstrated no significant relationship between LA pump function and 
indexed LV interstitial volume. This may suggest a greater LV fibrotic burden is 
required to cause LA pump dysfunction than is required to cause LA conduit or 
reservoir dysfunction. A prior CMR study in 210 hypertensive subjects[6] support this 
notion where, during a median 19 month follow-up, contractile atrial dysfunction 
was an independent predictor of major adverse clinical events(MACE)[6]. 
Furthermore, preservation of the proportion of LA contraction to total LV diastolic 
filling was strongly associated with lower MACE[6]. Decreased LA contractile 
function may identify those with the most LV diastolic dysfunction and conceivably 
these are the patients with the most diffuse LV fibrosis. It is therefore possible that 
failure of LA pump function fails heralds near end-stage hypertensive cardiac end-
organ damage, accounting for the correlation of this imaging biomarker with 
mortality[6]. Therefore, therapeutic targeting of diffuse LV myocardial fibrosis prior 
to the onset of overt LA contractile dysfunction may offer the best chance of 
achieving LA reverse remodeling. Treatment with angiotensin converting enzyme 
inhibitors and angiotensin II receptor blockers have been associated with LA reserve 
remodeling in both the spontaneously hypertensive rat[29] and in hypertensive 
humans[30]. The putative mechanisms by which these agents result in LA reverse 
remodeling are incompletely understood, potentially include downstream effects of 
BP reduction or improved LV diastolic function. However, direct suppression of the 
renin-angiotensin-aldosterone system is also implicated. Our results, showing a 
correlation between LV fibrosis and LA volume, may offer further pathophysiological 
insights. Such agents have been demonstrated to result in regression of LV fibrosis in 
murine models of hypertension[31], which could be a common driver of the LV 
 16 
diastolic functional improvement and improvement in LA function and structure. 
Although not assessed in the current study, it is possible that these drugs cause 
direct regression of LA fibrosis, having been associated with a reduction in the 
percentage of fibrosis of LA tissue in spontaneously hypertensive rats treated with 
Olmesartan compared to controls[29]. 
 
Clinical implications 
The clinical prognostic importance of LAV independent to LV diastolic dysfunction is 
debated. In a study of 1,160 elderly patients with cardiovascular disease referred for 
routine clinical echocardiography, both LV diastolic dysfunction and indexed LAVmax 
were independent predictors of cardiovascular events[32]. In a younger cohort of 
484 subjects in sinus rhythm referred for echocardiography, an elevated indexed 
LAVmax was the only independent predictor of cardiovascular death and events, and 
indices of LV diastolic dysfunction were not[33]. Many previous studies have focused 
on LAVmax but in a study of 41 patients undergoing invasive pressure measurements 
via left heart cardiac catheterization and CMR on the same day, increased LAVmin 
had the best ability to predict elevated LV end-diastolic filling pressure[34]. 
Furthermore, a prior echocardiographic study showed that LAVmin significantly 
increased with worsening LV diastolic dysfunction and in multivariate models, 
increasing LAVmin was independently associated with decreasing echocardiographic 
indices of LV diastolic function, but LAVmax was not[35]. Our study helps explain this 
by demonstrating a statistically stronger correlation between ECV and indexed 
LAVmin, than with LAVmax. We also found significant correlation between peak 
circumferential strain, peak circumferential systolic strain rate and peak 
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circumferential diastolic strain rate and indexed LAVmin. These findings support the 
notion that diffuse LV fibrosis is associated with LV diastolic dysfunction, elevated LV 
end-diastolic filling pressure and in turn LAVmax and LAVmin dilatation. However, 
whether the fibrotic process starts in the LV and that drives the LA changes, or 
whether the same fibrotic process occurs simultaneous in the LV and LA remains 
unanswered. 
 
LA function is also of prognostic importance. In the Dallas Heart CMR study of 1,802 
subjects, decreasing LAEF, defined as (LAVmax – LAVmin)/LAVmax x 100), was 
independently associated with mortality[36]. We show a correlation between 
declining total LA emptying fraction and diffuse LV fibrosis. Furthermore, we 
demonstrate a significant decrease in LA expansion index, a parameter that predicts 
LV filling pressure[12], severe LV diastolic dysfunction[13] and all-cause 
mortality[11], with increasing LV interstitial volume.  
 
Our study highlights the central pathophysiological role of LV diffuse myocardial 
fibrosis in hypertension. The LV fibrotic burden has associations with structural and 
functional changes beyond the LV. This suggests that targeting LV fibrosis should be 
a key therapeutic target but effective anti-fibrotic treatments have proven to be an 
elusive until very recently. New insights into both the understanding of the 
development of myocardial fibrosis and novel ways in which to abrogate this 
process, such as inhibition of interleukin-11[37], at least in animal models, offers 
hope that the effective therapies for blocking/reversing myocardial fibrosis may be 
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on the horizon, which may improve LV and LA structure and function in 
hypertension.  
 
Study limitations 
The study was performed in a specialist hypertension clinic population. Further study 
is required in a larger, more diverse population to enable further analyses such as 
impact of duration of hypertension and anti-hypertensive regimens on LV diffuse 
myocardial fibrosis and LA structure/function. 
 
T1 values were recorded in mid-septum owing to lower intra-observer, inter-
observer and inter-study variability previously reported in the lateral wall, likely 
related to a number of confounders, e.g. magnetic susceptibility artifact, receiver 
coil sensitivity and distance from the receiver coil elements[38]. Nevertheless, more 
comprehensive segmental T1 quantification has been described[39], but not 
performed in the current study. Hypertensive remodeling may begin in the 
septum[40] and therefore only measuring T1 relaxation values here could 
theoretically result in a overestimation of the degree of interstitial expansion. 
 
LA conduit function was defined as passive emptying fraction. This is an index of one 
component of conduit function as it only describes the flow that results from change 
in LA volume during this time interval rather than the entire flow from the 
pulmonary veins through the LA into the LV during that phase of diastole. 
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Contemporaneous comprehensive echocardiographic assessment was not available 
in all study subjects. CMR strain rates have been provided but may be limited by 
inferior temporal resolution of CMR to echocardiography. Future work could 
investigate whether diffuse LV myocardial fibrosis is the underlying 
pathophysiological abnormality, which independently causes both LV diastolic 
dysfunction and LA dilatation and dysfunction. 
 
LA replacement fibrosis assessment, with LGE or T1 mapping, was not investigated, 
but may be potentially important[41].  
 
Conclusion 
In hypertension, increasing LV interstitial fibrosis is associated with LAE and impaired 
LA function. ECV was the strongest significant independent predictor of LAE in 
multivariate analysis, and increasing indexed LV interstitial volume significantly and 
independently resulted in worsening LA reservoir function. Diffuse LV fibrosis may 
represent a key therapeutic target for reverse remodeling of both LA and LV 
structural and functional abnormalities in hypertension. 
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Figure legends 
Figure 1: The biplane area-length method to measure LAV. LAVmax was measured at 
maximal atrial dilatation occurring at LV end-systole just before mitral valve opening, 
as before. Briefly, the image on A) LV long-axis 4-chamber (A1 = atrial area, L1 = 
atrial length) and B) 2-chamber SSFP cines (A2 = atrial area, L2 = atrial length) 
immediately preceding the opening of the mitral valve was used for analysis of 
LAVmax. First, LA length was measured from the mitral annular plane to the 
posterior aspect of the LA wall, parallel to the LV long-axis on both 4-chamber and 2-
chamber SSFP cines. The endocardial border of the LA was also manually contoured 
at LAVmax, excluding the LA appendage and pulmonary venous confluence. RA=right 
atrium, RV=right ventricle, LV=left ventricle 
 
Figure 2: The phasic volumetric method for assessing left atrial function. A) LAVmin 
measured at mitral valve closure. B) LAVpre-A measured just prior to left atrial 
contraction. C) LAVmax measured just before mitral valve opening. RA = right 
atrium, RV = right ventricle, LV = left ventricle 
 
Figure 3: Study design and exclusions. *Image artifact from implantable loop 
recorder device precluding volumetric assessment from LV short axis SSFP cine stack. 
 
Figure 4: A & B) The relationship between LV mass and LA volume in 86 hypertensive 
patients (n=23 with LAE, n=63 without LAE) and 20 controls. A) Scatterplot 
demonstrates positive correlation between indexed LV mass and indexed LAVmax 
(R=0.376, P<0.0001). B) Scatterplot demonstrates positive correlation between 
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indexed LV mass and indexed LAVmin (R=0.616, P<0.0001). 4 C & D) The relationship 
between LAVmax and LV fibrosis in 86 hypertensive patients (n=23 with LAE, n=63 
without LAE). C) Scatterplot demonstrates positive correlation between ECV and 
indexed LAVmax (R=0.359, P=0.001). D) Scatterplot demonstrates positive 
correlation between ECV and indexed LAVmin (R=0.390, P<0.0001). 
 
Figure 5: Relationship between LA function and LV fibrosis in 86 hypertensive 
patients (n=23 with LAE, n=63 without LAE). A) Scatterplot demonstrates negative 
correlation between indexed myocardial interstitial volume and LA total reservoir 
function (R=-0.437, P<0.0001). B) Scatterplot demonstrates negative correlation 
between indexed myocardial interstitial volume and LA passive conduit function (R=-
0.316, P=0.003). C) There was no significant correlation between indexed interstitial 
volume and LA contractile pump function (R=-0.167, P=0.125). D) Scatterplot 
demonstrates negative correlation between indexed myocardial interstitial volume 
and LA expansion index (R=-0.377, P<0.0001). 
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Table 1: Scan parameters for native and post contrast T1-mapping sequences  
 
Native T1-mapping     Post contrast T1-mapping 
HR < 90 bpm  HR > 90 bpm   HR < 90 bpm  HR > 90 bpm 
TR (ms)    314.85   374.95    394.85   374.95 
TE (ms)    1.12   1.00    1.12   1.00 
Slice thickness (mm)  8    8    8   8 
Voxel size (mm)  2.1 x 1.4 x 8  2.4 x 1.9 x 8   2.1 x 1.4 x 8  2.4 x 1.9 x 8 
Matrix    144 x 256  128 x 192   144 x 256  128 x 192    
No. acquired heart beats 5   5    4   4 
No. recovery heart beats 3   3    1   1 
 
 
HR = heart rate, bpm = beats per minute, TR = repetition time, TE = echo time, ms = milliseconds, mm = millimetres 
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Table 2: Demographic and CMR data  
 
                   Hypertensive 
 
Controls (n=20)  No LAE (n=63)   LAE (n=23)   
  
Age (year)      48.±.13   48.±.14   52.±.14 
Gender (% male)     55    60    48 
BMI (kg/m2)      28.±.5    31.±.6    30.±.6 
Diabetes mellitus (%)     0    13    9 
Heart rate (beats/min)     71.±10    73.±.13   64.±.10^^^ 
Office systolic blood pressure (mmHg)  130.± 13   166.± .27 §§§   169.± .35 *** 
Office diastolic blood pressure (mmHg)  80.±.11   96.±.12 §§§   97.±.17 ***  
ESH/ESC office BP grade  
- Controlled (%)      …    6     13  
- High normal (%)     …    3     4  
- Grade 1 (%)      …    30    26 
- Grade 2 (%)      …    32    13 
- Grade 3 (%)      …    27    39 
- Isolated systolic (%)     …    3    4 
No. antihypertensive medications (n)   0    2 ± 2    3 ± 2 *** 
ACEi/ARB (%)      0    76    83 *** 
 
One-way ANOVA with Bonferonni post-hoc correction or Chi squared test as appropriate: 
Controls vs LAE: *** p < 0.001 
Controls vs No LAE : §§§ p < 0.001 
LAE vs No LAE: ^^^ p <0.001, LAE vs No LAE 
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Table 3: Demographic and CMR data  
 
                   Hypertensive 
 
Controls (n=20)  No LAE (n=63)   LAE (n=23)   
  
LV data 
EF.(%)       66.±.8    68.±.8    64.±.11 
Indexed EDV.(ml/m2)     70.±.12   73.±.16   89.±.17 *** ^^^  
Indexed ESV.(ml/m2)     24.±.7    24.±.10   34.±.17 * ^^^  
Indexed SV.(ml/m2)     46.±.9    49.± 10   56.±.10 ** ^ 
Cardiac output.(l/min1)     6.3.±.1.4   6.6.±.3.0   6.7.±.2.1 
Mass : volume.(g/ml)     0.82.±.0.13   1.16.±.0.30 §§§   1.12.±.0.41 ** 
Indexed LV mass.(g/m2)    56.±.8    84.±.22 §§§   97.±.33 *** ^ 
 
LV strain data 
Peak circumferential strain (%)    -17.6 ± 2.7   -16.8 ± 3.2   -15.7 ± 4.2 
Peak circumferential systolic strain rate (%/sec) -102.7 ± 13.4   -108.7 ± 29.7   -86.4 ± 24.8 ^^ 
Peak circumferential diastolic strain rate (%/sec) 102.3 ± 26.9   94.5 ± 24.9   83.3 ± 31.9 
 
                Continued… 
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Table 3: Demographic and CMR data continued 
 
                   Hypertensive 
 
Controls (n=20)  No LAE (n=63)   LAE (n=23)   
  
LV T1 mapping data 
Native T1.(ms)      1030.±.42   1039.±.36   1044.±.52 
ECV.(%)       …    27.±.3    30.±.4 ^^ 
Indexed interstitial volume.(ml/m2)   …    21.±.7    28.±.12 ^ 
Indexed myocardial cell volume.(ml/m2)  …    57.±.15   64.±.21  
 
LA data 
Indexed LAVmax.(ml/m2)    38.±.8    42.±.8    65.±.8 *** 
Indexed LAVmin.(ml/m2)    16.±.3    20.± .6 §   34.±.10 *** 
Reservoir function.(%)     57 ±.9    51.±.9 §   47.±.11 ** 
Conduit function.(%)     35.± .10   28.±.12   26.±.9 * 
Pump function.(%)     33.±.9    31.±.13   30.± 11 
Expansion index.(%)     133.± .31   114 ± 38   96 ± 37 ** 
 
 
One-way ANOVA with Bonferonni post-hoc correction: 
Controls vs LAE:  * p < 0.05, Controls vs LAE   ** p < 0.01, Controls vs LAE   *** p < 0.001, Controls vs LAE 
Controls vs No LAE: § p < 0.05, Controls vs No LAE  §§ p < 0.01, Controls vs No LAE  §§§ p < 0.001, Controls vs No LAE 
LAE vs No LAE:  ^ p < 0.05 LAE vs No LAE   ^^ p < 0.01, LAE vs No LAE   ^^^ p <0.001, LAE vs No LAE 
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Table 4: CMR data corrected for covariates¶ 
 
                   Hypertensive 
 
Controls (n=20)  No LAE (n=63)   LAE (n=23)   
  
LV data 
EF.(%)       65 ± 2    68 ± 1    64 ± 2 
Indexed EDV.(ml/m2)     74 ± 2    72 ± 16   89 ± 3  * ^^^   
Indexed ESV.(ml/m2)     28 ± 3    24 ± 2    33 ± 2 ^^ 
Indexed SV.(ml/m2)     47 ± 3    49 ± 1    56 ± 2 * ^ 
Cardiac output.(l/min1)     6.9 ± 0.8   6.4 ± 0.3   6.7 ± 0.6 
Mass : volume.(g/ml)     0.94 ± 0.09   1.12 ± 0.04   1.12 ± 0.06 
Indexed LV mass.(g/m2)    72 ± 6    79 ± 2    95 ± 4 ** ^^ 
 
LV strain data 
Peak circumferential strain (%)    -15.8 ± 0.8   -17.3 ± 0.4   -15.9 ± 0.6 
Peak circumferential systolic strain rate (%/sec) -89.5 ± 6.6   -111.2 ± 3.3 §   -90.0 ± 7.4 ^^ 
Peak circumferential diastolic strain rate (%/sec) 89.5 ± 6.6   97.6 ± 2.9   86.2 ± 4.8 
 
        
                Continued… 
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Table 4: CMR data corrected for covariates¶ continued 
 
                   Hypertensive 
 
Controls (n=20)  No LAE (n=63)   LAE (n=23)   
  
LV T1 mapping data 
Native T1.(ms)      1047 ± 12   1036 ± 5   1042 ± 9 
ECV.(%)       …    27 ± 4    30 ± 6 ^^^ 
Indexed interstitial volume.(ml/m2)   …    21 ± 1    29 ± 2 ^^^ 
Indexed myocardial cell volume.(ml/m2)  …    57 ± 2    65 ± 3 ^ 
 
LA data 
Indexed LAVmax.(ml/m2)    40 ± 2    42 ± 1    64 ± 2 *** ^^^  
Indexed LAVmin.(ml/m2)    19 ± 2    20 ± 1    34 ± 1 *** ^^^ 
Reservoir function.(%)     53 ± 3    52 ± 1    48 ± 2 
Conduit function.(%)     32 ± 3    29 ± 1    26 ± 2 
Pump function.(%)     30 ± 3    32 ± 1    30 ± 2 
Expansion index.(%)     124 ± 11   115 ± 5   103 ± 7 
 
¶General linear models accounting for the covariates of age, gender, BMI, diabetes, office SBP and DBP and number of anti-hypertensive 
medications. Data are presented as mean ± standard error. 
 
One-way ANOVA with Bonferonni post-hoc correction: 
Controls vs LAE:  * p < 0.05, Controls vs LAE   ** p < 0.01, Controls vs LAE   *** p < 0.001, Controls vs LAE 
Controls vs No LAE: § p < 0.05, Controls vs No LAE  §§ p < 0.01, Controls vs No LAE  §§§ p < 0.001, Controls vs No LAE 
LAE vs No LAE:  ^ p < 0.05 LAE vs No LAE   ^^ p < 0.01, LAE vs No LAE   ^^^ p <0.001, LAE vs No LAE 
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Table 5: Determinants of LAE 
 
 
                   Univariate analysis                         Multivariate analysis  
      OR (95% CI)   P-value  OR (95% CI)   P-value 
Age.(years)    1.02 [0.98–1.05]  =0.309   …    … 
Male gender    1.66 [0.63–4.34]  =0.302   …    … 
BMI.(kg/m2)    0.97 [0.88–1.05]  =0.427   …    … 
Office SBP.(mmHg)    1.00 [0.99–1.02]  =0.688   …    … 
Office DBP.(mmHg)   1.01 [0.97–1.04]  =0.784   …    … 
Diabetes mellitus   1.53 [0.30–7.79]  =0.610   …    … 
Indexed LV mass.(g/m2)  1.02 [1.00–1.04]  =0.034*  1.00 [0.98–1.02]  =0.938 
ECV.(%)     1.30 [1.10–1.54]  =0.002*  1.24 [1.04–1.48]  =0.017* 
Peak circ systolic strain rate (%/sec) 1.04 [1.01–1.07]  =0.003*  1.04 [ 1.01–1.07]  =0.022* 
 
 
 
OR=odds ratio, CI=confidence interval, * P<0.05 
